DeniLA: Comprehensive Demographics and Clinical Profile of NSCLC Patients: Analyzing Guideline-Concordant Care in First-line Treatment Patterns
NCT07109154 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 200
Last updated 2026-05-13
Summary
This is a prospective, observational, multicenter study, in which clinical and demographic data will be extracted from medical records. Convenience sample, with an estimated inclusion of 200 patients treated in seven participating centers.
Eligible tumors for this project will be from patients with advanced (unresectable or metastatic) non-small cell lung carcinoma, who will start first-line oncological treatment in one of the participating centers between 2025 and 2026 (between January 2025 and January 2026). Patients must be over 18 years old and data must be available in electronic medical records.
Medical records will be assessed to confirm patients' eligibility. Patients with localized disease amenable to local treatment, non-epithelial histology, small cell carcinoma and neuroendocrine tumor will not be eligible.
A survey will be designed targeting thoracic and generalist medical oncologists, aiming to understand the factors guiding the choice of first-line treatment regimens and to compare these insights with real-world data. The survey will be directed to Brazil, with an estimated of 200 filled files.
Conditions
- Lung Neoplasms
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Clarissa Baldotto · Instituto D'Or de Pesquisa e Ensino
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-11-25
- Primary Completion
- 2027-04-30
- Completion
- 2027-04-30
Countries
- Brazil
Study Locations
More Related Trials
-
Denosumab and Nivolumab Combination As 2d-line Therapy in Stage IV NSC Lung Cancer with Bone Metastases (DENIVOS)
NCT03669523 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT06624059 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Study of S-588410 After Adjuvant Chemotherapy for Completely Resected Non-small- Cell Lung Cancer
NCT02410369 ·Status: UNKNOWN ·Phase: PHASE2
-
Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
NCT01951586 ·Status: COMPLETED ·Phase: PHASE2
-
RACE-2L: Real-World Assessment of Clinical Practice and Outcomes in Non-squamous NSCLC After Failure of Platinum-based Chemotherapy in Brazil
NCT06491862 ·Status: RECRUITING
-
Study of the Efficacy of an Investigational Drug in Adult Patients With Non Small-Cell Lung Cancer (NSCLC)
NCT00034957 ·Status: COMPLETED ·Phase: PHASE2
-
Paclitaxel/Carboplatin (PC) Followed by Gefitinib Versus PC in Advanced Non-small Cell Lung Cancer
NCT01196234 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of the Overall Survival of Meclinertant Versus Placebo After a First Line Chemotherapy With Cisplatin + Etoposide
NCT00290953 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Pegylated Liposomal Doxorubicin and Carboplatin as First Line Treatment for Patients With Advanced Non-small Cell Lung Cancer
NCT01051362 ·Status: UNKNOWN ·Phase: PHASE2
-
Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1%
NCT07215962 ·Status: ACTIVE_NOT_RECRUITING
-
Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer
NCT04262856 ·Status: COMPLETED ·Phase: PHASE2
-
Observational Study of Patients With Locally Advanced or Metastatic NSCLC (Non-Small Cell Lung Cancer)
NCT03053297 ·Status: TERMINATED
-
PD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung Cancer
NCT06429696 ·Status: RECRUITING ·Phase: PHASE2
-
Patient and Physician Preference Study in Resectable, Non-small Cell Lung Cancer Treatments
NCT06448793 ·Status: RECRUITING
-
The Efficacy and Safety of PD-1/PD-L1 Inhibitors Combined With Centipeda Minima (CM) in Lung Cancer
NCT05735028 ·Status: RECRUITING ·Phase: PHASE1
-
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
NCT07144280 ·Status: RECRUITING ·Phase: PHASE3
-
Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung Cancer
NCT03419559 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy
NCT05450692 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for Chemotherapy
NCT04249362 ·Status: COMPLETED ·Phase: PHASE2
-
Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC)
NCT04255836 ·Status: UNKNOWN ·Phase: PHASE2
-
Serplulimab Combined With Chemotherapy in Patients With Resectable Non-small-cell Lung Cancer
NCT05882513 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Treatment Patterns in Advanced Small Cell Lung Cancer (SCLC)
NCT03425825 ·Status: COMPLETED
-
AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.
NCT02511106 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer
NCT05353257 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1
NCT02855125 ·Status: COMPLETED ·Phase: PHASE2